Plain-English translation of NCT07397650 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
FACILITATE-HF is testing a medication called finerenone to see if giving it early during hospitalization for acute heart failure helps patients. The trial will randomly assign 550 patients to either receive finerenone or a placebo (a tablet with no active medication). Researchers want to learn whether starting this medication early in a hospital stay can safely improve outcomes for people with heart failure.
Acute heart failure is a serious condition that often requires hospitalization and IV medications. Doctors want to know if starting this medication early during the hospital stay — rather than waiting — could help patients recover faster and reduce the risk of complications or readmission.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be randomly assigned to either take finerenone or placebo tablets by mouth starting within 36 hours of hospital admission. You must be randomized within 24 hours of arriving at the hospital. While hospitalized, you'll receive standard heart failure care and monitoring; the study medication is given in addition to your regular treatments. The trial follows your progress during and after your hospital stay to see how well the medication works and whether it's safe.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
Japan